This site is intended for
Healthcare Providers Only

Enhancing Postsurgical
Pain Control

A Surgeon's Experience on Applications for EXPAREL in Reconstructive Plastic Surgery

EXPAREL® Administration Video for Right Inguinal Hernia by Jerrold Young, MD.

EXPAREL Infiltration in Right Inguinal Hernia

In this video, Jerrold Young, MD, provides methodology for using EXPAREL in a specific soft tissue procedure.

Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and hemorrhoidectomy procedures.


To report an adverse event, e-mail drugsafety@pacira.com or dial 1-855-RX-EXPAREL (1-855-793-9727).

For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727).

EXPAREL Administration: Learn how clinicians are infiltrating EXPAREL in a variety of procedures

EXPAREL Administration

Learn how clinicians are infiltrating EXPAREL in a variety of procedures. > More


Sign up to receive updates on EXPAREL

Sign Up

Sign up to receive updates on EXPAREL. > Sign Up


These are not all of the potential important safety considerations for EXPAREL, please see the full Prescribing Information.

References:

  1. EXPAREL [prescribing information]. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; 2011.
  2. Gorfine SR, Onel E, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Diseases of the Colon & Rectum. 2011;54(12):1552-1559.
  3. Safe Use of Opioids. The Joint Commission Sentinel Event Alert. Issue 49; August 8, 2013.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age.


Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL.


Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations.


In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for EXPAREL.

EXPAREL® Sign Up


Sign up to receive updates on EXPAREL.

Required*

First name*

Last name*

E-mail*

ZIP code*

Providing the optional information about you below enables us to provide information geared to your needs.

Specialty




Yes, I would like to receive periodic updates about EXPAREL via e-mail. I agree to the Privacy Policy.

Thank you! Your registration is complete.

Sorry. There was an error submitting your request. Please try again at another time.

Sorry. The connection to the server was lost. Please try again at another time.

EXPAREL® E-mail


Required*

Your name:*

Your colleague's name:*

Your colleague's e-mail address:*

To learn about our use of your information and your rights, please consult our Privacy Policy.

Your email has been sent.
Thank you!

The email address you entered was invalid.

Unfortunately, your email could not be sent at this time.